{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:49:12Z","timestamp":1782190152631,"version":"3.54.5"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,7,20]]},"abstract":"Purpose<\/jats:title> To evaluate the effectiveness of prophylactic dexamethasone for the control of radiation induced emesis (RIE) when added to ondansetron during days 1 to 5 of fractionated radiotherapy. The study had two hypotheses: ondansetron and dexamethasone could provide superior control of RIE over ondansetron alone during the prophylactic period and; the combination could provide sustained control of RIE during subsequent fractions of radiotherapy. <\/jats:p><\/jats:sec>Patients and Methods<\/jats:title> Between May 2001 to Jan 2004, 211 patients receiving radiotherapy (\u2265 15 fractions) to the upper abdomen were randomly assigned to receive ondanstron 8 mg bid with either dexamethasone 4 mg daily or placebo during fractions 1 to 5. Rescue antiemetics were provided. <\/jats:p><\/jats:sec>Results<\/jats:title> During the prophylactic period there was a trend for improved complete control of nausea in the dexamethasone arm (50% v 38%; P = .06) while complete and partial control of emesis, average nausea score, and use of rescue medications were similar in the two groups. During the overall study period patients receiving dexamethasone had better complete control of emesis (23% v 12%; P = .02) and a lower average nausea score (0.28 v 0.39; P = .03); there was a trend towards less use of rescue medications with dexamethasone (70% v 80%; P = .09); other outcomes were similar on the two arms. Quality of life analysis showed a significant difference in appetite. <\/jats:p><\/jats:sec>Conclusion<\/jats:title> The addition of dexamethasone to ondansetron as prophylaxis provides a modest improvement in protection against RIE during moderately emetogenic fractionated radiotherapy. It is a potentially useful addition to 5-hydroxytryptamine-3 receptor antagonists in this setting. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.4685","type":"journal-article","created":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T23:08:23Z","timestamp":1153264103000},"page":"3458-3464","source":"Crossref","is-referenced-by-count":49,"title":["5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19)"],"prefix":"10.1200","volume":"24","author":[{"given":"Rebecca K.S.","family":"Wong","sequence":"first","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Paul","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyue","family":"Ding","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlo","family":"Whitehead","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brundage","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fyles","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wilke","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdenour","family":"Nabid","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Fortin","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McKenzie","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Ackerman","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Souhami","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Chabot","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pater","sequence":"additional","affiliation":[{"name":"From the National Cancer Institute of Canada Clinical Trials Group; Kingston Regional Cancer Centre, Queen's University, Kingston; Queen Elizabeth II Health Sciences Centre, Nova Scotia; Centre Hospitalier Universitaire de Sherbrooke Hopital Fluerimont, Sherbrooke; Centre Hospitalier Universitaire de Quebec Pavillon Hotel Dieu de Quebec, Hopital Maisonneuve Rosemont; McGill University, Department of Oncology; Centre Hospitalier de L'Universite de Montreal Hopital Notre-Dame, Quebec; Toronto Sunnybrook..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.4814.802"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(79)80203-2"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(91)90009-O"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Young R: Mechanisms and treatment of radiation induced nausea and vomiting, in Davis C, Lake-Bahrr G, Grahame-Smith D (eds): Nausea and Vomiting: Mechanisms and treatment. Berlin Heidelberg, Germany, Springer-Verlag, 1986","DOI":"10.1007\/978-3-642-70479-6_8"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00161-0"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/BF01788845"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2432"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010675"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(97)80011-8"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1053\/clon.1999.9077"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80790-3"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050119"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80086-X"},{"key":"R14","unstructured":"Prentice HG, Cunningham S, Gandhi L, et al: Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15:445,1995-448,"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1960"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.017"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2003.20203.x"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200110000-00002"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(03)00101-6"},{"key":"R22","unstructured":"Hauptman PJ: Measurement of end points in heart failure trials: Jousting at windmills? Mt Sinai J Med 71:298,2004-304,"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh322"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200210000-00004"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.07.009"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/56.8.729"},{"key":"R28","unstructured":"NCCN: NCCN antiemesis practice guidelines. Oncology (Huntington) 11:57,1997-89,"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2971"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0705-3"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.4685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:27:08Z","timestamp":1653514028000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.4685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,20]]},"references-count":28,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2006,7,20]]}},"alternative-id":["10.1200\/JCO.2005.04.4685"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.4685","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,20]]}}}